Literature DB >> 23542091

Physical harm due to chronic substance use.

Jan van Amsterdam1, Ed Pennings, Tibor Brunt, Wim van den Brink.   

Abstract

Chronic use at high dose of illicit drugs, alcohol and tobacco is associated with physical disease. The relative physical harm of these substances has not been described before, but will benefit the guiding of policy measures about licit and illicit substances. The physical harm of 19 addictive substances (including alcohol and tobacco), consisting of toxicity and the risk and severity of somatic disease (not psychiatric disease) was assessed based on literature data and the professional opinion of experts using scores ranging from 0 (no physical harm) to 3 (very serious physical harm). For alcohol, tobacco and some illicit drugs strong associations between long-term use or use in high dose versus the risk of somatic disease have been described, whereas for other substances such data are not available. Magic mushrooms, LSD and methylphenidate obtained relatively low scores (0.45-0.65) for physical harm, whereas relatively high scores were given for heroin (2.09), crack (2.32), alcohol (2.13) and tobacco (2.10). For cannabis, tobacco, and alcohol the estimated societal disease burden was higher than at individual level. The present ranking solely based on their physical harm was very similar to a previous ranking based on a combination of dependence liability, physical harm and social impairments.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23542091     DOI: 10.1016/j.yrtph.2013.03.007

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  8 in total

Review 1.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

Review 2.  Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Authors:  Rafael G Dos Santos; José Carlos Bouso; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2017-02-23

3.  Eating disorders and subsequent risk of substance use disorders involving illicit drugs: a Danish nationwide register-based cohort study.

Authors:  Lotte Skøt; Anna Mejldal; Maria Mercedes Guala; René Klinkby Støving; Leonie Ascone; Elsebeth Stenager; Mia Beck Lichtenstein; Angelina Isabella Mellentin
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-01-05       Impact factor: 4.328

Review 4.  An international smoking ban-how many lives will be saved?

Authors:  Cecily C Kelleher; Kate Frazer
Journal:  Curr Atheroscler Rep       Date:  2014-06       Impact factor: 5.113

5.  Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials.

Authors:  Juan José Fuentes; Francina Fonseca; Matilde Elices; Magí Farré; Marta Torrens
Journal:  Front Psychiatry       Date:  2020-01-21       Impact factor: 4.157

6.  Frequencies of emergency department use and hospitalization comparing patients with different types of substance or polysubstance-related disorders.

Authors:  Bahram Armoon; Guy Grenier; Zhirong Cao; Christophe Huỳnh; Marie-Josée Fleury
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-12-18

Review 7.  Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study.

Authors:  Yasaman Razavi; Fariborz Keyhanfar; Ronak Shabani; Abbas Haghparast; Mehdi Mehdizadeh
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

Review 8.  The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry.

Authors:  Joshua S Kurtz; Neal A Patel; Julian L Gendreau; Chenyi Yang; Nolan Brown; Nick Bui; Bryce Picton; Mark Harris; Matthew Hatter; Ryan Beyer; Ronald Sahyouni; Luis Daniel Diaz-Aguilar; Joel Castellanos; Nathaniel Schuster; Mickey E Abraham
Journal:  Cureus       Date:  2022-09-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.